Is EQ-5D a valid quality of life instrument in patients with acute coronary syndrome?

Süt, Hatice Kahyaoğlu; Ünsar, Serap

doi:10.5152/akd.2011.037

Cited by 24 publications

(9 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the EQ-5D questionnaire has been shown to have good validity and reliability, and is highly accepted by patients with acute coronary syndrome. [13][14][15] Finally, as we did not measure HRQOL during the 9 weeks of active treatment with bupropion, we cannot rule out a transient effect of the drug on HRQOL.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Bupropion, Smoking Cessation, and Health-Related Quality of Life Following an Acute Myocardial Infarction

Zhang¹,

Eisenberg²,

Grandi³

et al. 2013

Canadian Journal of Cardiology

View full text Add to dashboard Cite

BackgroundThe use of bupropion, a smoking cessation aid, has been associated with improved health-related quality of life (HRQOL) in the general population of smokers; but, its effect on HRQOL in post-myocardial infarction (MI) patients remains unknown. ObjectivesTo examine the effect of bupropion on HRQOL in post-MI patients who are attempting to quit smoking. MethodsTo accomplish this objective, we used data from a randomized, double-blind, placebo-controlled trial in 392 hospitalized post-MI patients. Treatment duration was 9 weeks, and follow-up was 12 months. HRQOL was assessed via the EuroQol-5D (EQ-5D) questionnaire, which includes 5 dimensions (mobility, self-care, daily activities, pain/discomfort, and anxiety/depression). Analyses were restricted to patients (n=225) who completed the EQ-5D at baseline, 6 months, and 12 months. ResultsPatients randomized to bupropion (n=109) and those randomized to placebo (n=116) experienced similar improvements in HRQOL during follow-up (difference in change in EQ-5D index from baseline to 6 months = 0.02, 95% confidence interval [CI] = -0.04, 0.08; from baseline to 12 months = 0.02, 95% CI = -0.04, 0.08). No between-group differences were observed in any of the 5 dimensions. Similar improvements in HRQOL were observed between patients who remained abstinent and those who relapsed. Lower baseline HRQOL, defined as having a HRQOL that was less than the median value, was associated with decreased smoking abstinence at 12 months follow-up (odds ratio OR =0.39, 95% CI = 0.22, 0.68). ConclusionsBupropion does not improve HRQOL among patients attempting to quit smoking post-MI.

show abstract

Section: Discussionmentioning

confidence: 99%

“…The EQ-5D questionnaire has been shown to be a valid, reliable, and responsive instrument to measure HRQOL in patients with an acute coronary syndrome. [13][14][15] Inclusion in the present study was restricted to participants who completed the EQ-5D questionnaire at baseline, 6 months, and 12 months.…”

Section: Study Populationmentioning

confidence: 99%

Bupropion, Smoking Cessation, and Health-Related Quality of Life Following an Acute Myocardial Infarction

Zhang¹,

Eisenberg²,

Grandi³

et al. 2013

Canadian Journal of Cardiology

View full text Add to dashboard Cite

show abstract

“…The EQ-5D-5L is valid and reliable for use in an online format [52]. The Turkish version has good validity and reliability properties [53].…”

Section: Methodsmentioning

confidence: 99%

Effectiveness of a Web- and Mobile-Guided Psychological Intervention for Depressive Symptoms in Turkey: Protocol for a Randomized Controlled Trial

İnce

Gökçay

Riper³

et al. 2019

JMIR Res Protoc

View full text Add to dashboard Cite

Background In Turkey, there are serious deficiencies in mental health care. Although depression is highly prevalent, only a small number of people seek professional help. Innovative solutions are needed to overcome this treatment gap. Web-based problem-solving therapy (PST) is an intervention proven to be effective in the treatment of depression, although little is known about its clinical effects in Turkey. Objective This study aims to test the clinical effects of a Web and mobile app of an adapted PST for depressive symptoms among the general population in Turkey. Methods Participants will be recruited through announcements in social media and the Middle East Technical University. Adults (18-55 years) with mild to moderate depressive symptoms (Beck Depression Inventory-II [BDI-II] score between 10-29) will be included in the study. Participants with a medium-to-high suicidal risk (according to the Mini-International Neuropsychiatric Interview) will be excluded. A 3-armed randomized controlled trial with a waiting control group will be utilized. A sample size of 444 participants will be randomized across 3 groups. The first experimental group will receive direct access to the Web version of the intervention; the second experimental group will receive direct access to the mobile app of the intervention as well as automated supportive short message service text messages based on PST. The control group consists of a wait-list and will gain access to the intervention 4 months after the baseline. The intervention is based on an existing PST for the Turkish population, Her Şey Kontrol Altında (HŞKA), consisting of 5 modules each with a duration of 1 week and is guided by a clinical psychologist. The primary outcome is change in depressive symptoms measured by the BDI-II. Secondary outcomes include symptoms of anxiety, stress, worry, self-efficacy, and quality of life. Furthermore, satisfaction with, usability and acceptability of the intervention are important features that will be evaluated. All outcomes will take place online through self-assessment at posttest (6-8 weeks after baseline) and at follow-up (4 months after baseline). Results We will recruit a total of 444 participants with mild to moderate depressive symptoms from March 2018 to February 2019 or until the recruitment is complete. We expect the final trial results to be available by the end of May 2019. This trial is funded by the Scientific and Technological Research Council of Turkey (National Postdoctoral Research Fellowship Programme 2016/1). Conclusions Results from this study will reveal more information about the clinical effects of HŞKA as well as its applicability in a Turkish setting through the Web and mobile platforms. On the basis of the results, a guided Web- and mobile-based PST intervention might become an appropriate alternative for treating mild to moderate depressive symptoms. ...

show abstract

“…The Euroqol 'EQ-5D 3 L' [42] will be used to measure general quality of life and the Seattle Angina Questionnaire (SAQ) [43] will be used to measure cardiac-specific quality of life. Both instruments have been validated when administered individually [43-46] and in combination [47] to assess quality of life in patients with coronary heart disease. In addition to a self-report of smoking status at baseline and the study endpoints, we will be further categorizing each smoker's dependence on cigarette smoking using the Fagerstrom Test for Nicotine Dependence (FTND) [48].…”

Section: Methodsmentioning

confidence: 99%

Home medicines reviews following acute coronary syndrome: study protocol for a randomized controlled trial

Bernal

Stafford

Bereznicki

et al. 2012

Trials

View full text Add to dashboard Cite

Background Despite continual improvements in the management of acute coronary syndromes, adherence to guideline-based medications remains suboptimal. We aim to improve adherence with guideline-based therapy following acute coronary syndrome using an existing service that is provided by specifically trained pharmacists, called a Home Medicines Review. We have made two minor adjustments to target the focus of the existing service including an acute coronary syndrome specific referral letter and a training package for the pharmacists providing the service. Methods/Design We will be conducting a randomized controlled trial to compare the directed home medicines review service to usual care following acute coronary syndromes. All patients aged 18 to 80 years and with a working diagnosis of acute coronary syndrome, who are admitted to two public, acute care hospitals, will be screened for enrolment into the trial. Exclusion criteria will include: not being discharged home, documented cognitive decline, non-Medicare eligibility, and presence of a terminal malignancy. Randomization concealment and sequence generation will occur through a centrally-monitored computer program. Patients randomized to the control group will receive usual post-discharge care. Patients randomized to receive the intervention will be offered usual post-discharge care and a directed home medicines review at two months post-discharge. The study endpoints will be six and twelve months post-discharge. The primary outcome will be the proportion of patients who are adherent to a complete, guideline-based medication regimen. Secondary outcomes will include hospital readmission rates, length of hospital stays, changes in quality of life, smoking cessation rates, cardiac rehabilitation completion rates, and mortality. Discussion As the trial is closely based on an existing service, any improvements observed should be highly translatable into regular practice. Possible limitations to the success of the trial intervention include general practitioner approval of the intervention, general practitioner acceptance of pharmacists' recommendations, and pharmacists' ability to make appropriate recommendations. A detailed monitoring process will detect any barriers to the success of the trial. Given that poor medication persistence following acute coronary syndrome is a worldwide problem, the findings of our study may have international implications for the care of this patient group. Trial registration Australian New Zealand Clinical Trials Registry ACTRN12611000452998

show abstract

Is EQ-5D a valid quality of life instrument in patients with acute coronary syndrome?

Cited by 24 publications

References 15 publications

Bupropion, Smoking Cessation, and Health-Related Quality of Life Following an Acute Myocardial Infarction

Bupropion, Smoking Cessation, and Health-Related Quality of Life Following an Acute Myocardial Infarction

Effectiveness of a Web- and Mobile-Guided Psychological Intervention for Depressive Symptoms in Turkey: Protocol for a Randomized Controlled Trial

Home medicines reviews following acute coronary syndrome: study protocol for a randomized controlled trial

Contact Info

Product

Resources

About